The Burden of Seasonal Influenza and Its Potential Complications Among Older Japanese Adults: A Real‐World Database Study

Takeshi Arashiro,Yuki Tajima,Yohei Ban,Matthew M. Loiacono,Masayo Ideguchi,Caroline de Courville

DOI: https://doi.org/10.1111/irv.70032

2024-11-16

Influenza and Other Respiratory Viruses

Abstract:Influenza and Other Respiratory Viruses, Volume 18, Issue 11, November 2024.

infectious diseases,virology

What problem does this paper attempt to address?

Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta‐analysis

Kiyosu Taniguchi,Shunya Ikeda,Yuriko Hagiwara,Daisuke Tsuzuki,Marwa Klai,Yoko Sakai,Bruce Crawford,Joshua Nealon

DOI: https://doi.org/10.1111/irv.12814

2020-09-30

Influenza and Other Respiratory Viruses

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Elderly populations are particularly vulnerable to influenza and often require extensive clinical support. In Japan, nationwide passive surveillance monitors seasonal influenza but does not capture the full disease burden. We synthesized existing evidence on the epidemiology, vaccine effectiveness (VE), and economic burden of seasonal influenza in the elderly population.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>PubMed, EMBASE, and ICHUSHI were searched for articles on seasonal influenza in Japan, published between 1997 and 2018, in English or Japanese. Grey literature was also assessed. A random‐effects meta‐analysis characterized VE of influenza vaccines among studies reporting this information.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Of 1,147 identified articles, 143 met inclusion criteria. Reported incidence rates varied considerably depending on study design, season, study setting and, most importantly, case definition. In nursing homes, the maximum reported attack rate was 55.2% and in the 16 articles reporting mortality rates, case fatality rates varied from 0.009% to 14.3%. Most hospitalizations were in people aged >60; healthcare costs were partially mitigated by vaccine administration. Meta‐analysis estimated overall VE of 19.1% (95% CI: 2.3% ‐ 33.0%) with a high proportion of heterogeneity (I<sup>2</sup>: 89.1%). There was a trend of lower VE in older people (40.1% [−57.3‐77.2] in the <65 group; 12.9% [−8.0‐29.8] in those 65; <i>P</i> = .21). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Despite differences between studies that make comparisons challenging, the influenza burden in elderly Japanese is significant. While vaccines are effective, current vaccination programs offer suboptimal protection. Health economic data and cost‐effectiveness analyses were limited and represent areas for policy‐relevant future research.</p></section>

infectious diseases,virology
Burden of influenza hospitalization among high-risk groups in the United States

DOI: https://doi.org/10.1186/s12913-022-08586-y

2022-09-29

BMC Health Services Research

Abstract:Seasonal influenza poses a substantial clinical and economic burden in the United States and vulnerable populations, including the elderly and those with comorbidities, are at elevated risk for influenza-related medical complications.

health care sciences & services
The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults

Jakob Langer,Verna L. Welch,Mary M. Moran,Alejandro Cane,Santiago M. C. Lopez,Amit Srivastava,Ashley Enstone,Amy Sears,Kristen Markus,Maria Heuser,Rachel Kewley,Isabelle Whittle

DOI: https://doi.org/10.1007/s12325-023-02770-0

2024-01-24

Advances in Therapy

Abstract:Adults aged ≥ 65 years contribute a large proportion of influenza-related hospitalizations and deaths due to increased risk of complications, which result in high medical costs and reduced health-related quality of life (HRQoL). Although seasonal influenza vaccines are recommended for older adults, the effectiveness of current vaccines is dependent on several factors including strain matching and recipient demographic factors. This systemic literature review aimed to explore the economic and humanistic burden of influenza in adults aged ≥ 65 years.

pharmacology & pharmacy,medicine, research & experimental
Burden of respiratory syncytial virus infections in older adults with acute respiratory infection in Japan: An epidemiological study among outpatients

Hiroyuki Ohbayashi,Takayuki Sakurai,Daisuke Himeji,Yasushi Fukushima,Hiroshi Takahashi,Arihiro Kiyosue,Eliazar Sabater Cabrera,Taizo Matsuki,Daniel Molnar,Victor Preckler Moreno,Silvia Damaso,Jean-Yves Pirçon,Maria Moitinho de Almeida

DOI: https://doi.org/10.1016/j.resinv.2024.06.003

Abstract:Background: Respiratory syncytial virus (RSV) is a leading cause of acute respiratory illness, with severe outcomes in older adults. Information on the prevalence, hospitalization rate, and impact on the health-related quality of life (HRQoL) of RSV in older adults with acute respiratory infections (ARI) in outpatient settings in Japan is limited. Methods: This multi-center epidemiological study included outpatients aged ≥60 years presenting with ARI between August 2021 and February 2023. Nasal and throat swabs were collected and tested by reverse transcription polymerase chain reaction (RT-PCR). The prevalence of RT-PCR-confirmed RSV (cRSV)-ARI, cRSV-lower respiratory tract disease (LRTD), and other respiratory viruses was calculated by season, region, age group, and RSV subtype. HRQoL was assessed via patient-reported outcomes. Results: The study included 923 ARI episodes (cRSV-ARI: N = 24; non-cRSV-ARI: N = 899). In years 1 and 2 (August 2021-July 2022 and August 2022-February 2023), the prevalence of cRSV-ARI was 2.5% and 2.8%, respectively. There was a predominance of RSV-B and RSV-A subtypes in years 1 and 2, respectively. In years 1 and 2 combined, 37.5% of cRSV-ARI cases had lower respiratory tract infection; all cRSV-LRTD cases occurred in those aged 60-74 years. RSV-ARI cases reported throat, chest, and respiratory symptoms, leading to impaired functioning and HRQoL. Conclusions: During the observed study period, RSV was circulating among older adults in Japan. RSV was a leading cause of ARI and LRTD. More data are needed to fully clarify the burden of RSV among older adults in Japan.
Impact of Age and Comorbid Conditions on Incidence Rates of COVID‐19‐Associated Hospitalizations, 2020–2021

Lisa Saiman,Edward E. Walsh,Angela R. Branche,Angela Barrett,Luis Alba,Sonia Gollerkeri,Julia A. Schillinger,Matthew Phillips,Lyn Finelli

DOI: https://doi.org/10.1111/irv.70016

2024-11-27

Influenza and Other Respiratory Viruses

Abstract:Influenza and Other Respiratory Viruses, Volume 18, Issue 11, November 2024.

infectious diseases,virology
The burden of disease and vaccine prevention of influenza in the elderly, patients with chronic diseases and health personnel

Yu-kai HUANG,Tao ZHANG,Gen-ming ZHAO

DOI: https://doi.org/10.16462/j.cnki.zhjbkz.2017.04.023

2017-01-01

Abstract:Influenza,a highly contagious viral infection,affects mainly the nose,throat,bronchi and lungs.It is easily transmitted via droplets through coughing or sneezing.Most will recover within one to two weeks without medical care after infection.For older people and those with certain health conditions,however,it may result in hospitalization or even death.Receiving an annual vaccination is the best way to prevent influenza.This study aims to describe the burden of disease and vaccine prevention among these higher risk groups.
Factors associated with the development of bacterial pneumonia related to seasonal influenza virus infection: a study using a large-scale health insurance claim database

Masahiro Shirata,Isao Ito,Taisuke Jo,Tomohide Iwao,Issei Oi,Nobuyoshi Hamao,Kensuke Nishioka,Hayato Yamana,Takahide Nagase,Hideo Yasunaga,Toyohiro Hirai

DOI: https://doi.org/10.1093/ofid/ofad222

2023-04-21

Open Forum Infectious Diseases

Abstract:Abstract Background Influenza-related bacterial pneumonia is a leading complication of influenza infection. However, the differences in the incidence rates and risk factors associated with concomitant viral/bacterial pneumonia (CP) and secondary bacterial pneumonia following influenza (SP) remain unclear. This study aimed to clarify the incidence rates of CP and SP following seasonal influenza and identify factors associated with their development. Methods This retrospective cohort study was conducted using the JMDC Claims Database, a health insurance claims database in Japan. All patients aged <75 years who developed influenza during 2 consecutive epidemic seasons 2017/2018 and 2018/2019 were analyzed. CP was defined as bacterial pneumonia diagnosed between 3 days before and 6 days after the date of influenza diagnosis, and SP was defined as pneumonia diagnosed 7–30 days after the date of diagnosis. Multivariable logistic regression analyses were performed to identify factors associated with the development of CP and SP. Results Among the 10,473,014 individuals registered in the database, 1,341,355 patients with influenza were analyzed. The average age at diagnosis was 26.6 (standard deviation, 18.6) years. There were 2,901 (0.22%) and 1,262 (0.09%) patients who developed CP and SP, respectively. Aged 65–74 years, asthma, chronic bronchitis/emphysema, cardiovascular disease, renal disease, malignant tumor, and immunosuppression were significant risk factors for both CP and SP, whereas cerebrovascular disease, neurological disease, liver disease, and diabetes were risk factors specific for CP development. Conclusions The results determined the incidence rates of CP and SP and identified their risk factors, such as older age and comorbidities.

immunology,infectious diseases,microbiology
Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data

Kohei Uemura,Sachiko Ono,Nobuaki Michihata,Hayato Yamana,Hideo Yasunaga

DOI: https://doi.org/10.1016/j.vaccine.2023.03.066

IF: 4.169

2023-05-05

Vaccine

Abstract:Background: The immune response to influenza vaccination in the elderly is likely to be lower than that in young adults. Clinical protection may not persist year-round in the elderly. However, the effectiveness of influenza vaccine in the elderly has not been adequately studied, especially in terms of the duration of effectiveness. Methods: We used a linked database of healthcare administrative claims data and vaccination records maintained by the municipality of a city in Kanto region of Japan. We studied individuals who were aged 65 years or older at baseline and were followed up between April 1, 2014 to March 31, 2020. The duration of influenza vaccine effectiveness by age category was analyzed using a time-dependent piecewise Cox proportional hazard model with time-dependent vaccine status, prior season vaccination and covariates confirmed in the baseline period (age, sex, cancer, diabetes, chronic obstructive pulmonary diseases, asthma, chronic kidney diseases, and cardiovascular diseases). Results: We identified an analysis population of 83,146 individuals, of which 7,401 (8.9%) had experienced influenza and 270 (0.32%) underwent influenza-related hospitalization. Individuals who were vaccinated during the first season (n = 47,338) were older than non-vaccinated individuals (n = 35,808) (average age, 75.8 vs. 74.1 years, respectively). The multivariable analysis showed a lower incidence of influenza in vaccinated individuals (hazard ratio [HR], 0.47; 95% confidence interval [CI], 0.43-0.51; P < 0.001), while the incidence of hospitalization for influenza did not differ significantly by vaccination status (HR, 0.79; 95% CI, 0.53-1.18; P = 0.249). Protective effectiveness against incidence was maintained for 4 or 5 months after vaccination in those aged 65-69 and 80-years, 5 months in 70-79 years. Conclusions: Our study identified moderate vaccine effectiveness in preventing the incidence of influenza in the Japanese elderly. Vaccine effectiveness showed a trend of gradual attenuation. Clinicians should suspect influenza infection even in those vaccinated, especially in elderly individuals who had received vaccination more than 4 or 5 months previously.
Incidence of hospitalisation for severe complications of influenza virus infection in Japanese patients between 2012 and 2016: a cross-sectional study using routinely collected administrative data

Hiroshi Yokomichi,Mie Mochizuki,Joseph Jonathan Lee,Reiji Kojima,Tetsuji Yokoyama,Zentaro Yamagata

DOI: https://doi.org/10.1136/bmjopen-2018-024687

IF: 3.006

2019-01-01

BMJ Open

Abstract:Objective To calculate the incidence of hospitalisation due to acute respiratory failure, pneumonia, acute respiratory distress syndrome (ARDS), febrile seizures and encephalitis/encephalopathy among influenza-positive patients in Japan, where point-of-care tests are routinely used to diagnose influenza. Design A cross-sectional study using routinely collected data. Setting Japanese clinics and hospitals between 2012 and 2016. Participants Japanese patients aged 0–74 years diagnosed with influenza by a rapid test in employment-related health insurance records. Primary outcome measures Incidence of hospitalisation per 100 000 influenza-positive episodes. Results We included over 16 million influenza-positive episodes, 1.0% of whom were hospitalised. Of these, 3361 were acute respiratory failure, 27 253 pneumonia, 18 ARDS, 2603 febrile seizure and 159 encephalitis/encephalopathy. The percentage of hospitalisations by age was 2.96% of patients aged 0–1 years, 0.77% aged 2–5, 0.51% aged 6–12, 0.78% aged 13–18, 1.36% aged 19–44, 1.19% aged 45–64, and 2.21% aged 65–74. The incidence of hospitalisations from these five complications combined was highest in influenza-positive patients aged 0–1 years (943 per 100 000) compared with 307 in those aged 2–5 years and 271 in those aged 65–74 years. For pneumonia, the incidence was highest for influenza-positive patients aged 0–5 years and 65 years or more. There were statistically significant decreasing trends over the years in the incidence of all-cause hospitalisations, pneumonia and febrile seizures. Conclusions Japanese administrative data revealed that 1.0% of influenza-positive patients aged under 75 years were hospitalised. Male patients had a higher incidence of pulmonary complications and febrile seizures. Children aged 0–5 years and adults aged 65–74 years were at high risk of being admitted to hospital for pneumonia.

medicine, general & internal
Observational Study on the Clinical Reality of Community-Acquired Respiratory Virus Infections in Adults and Older Individuals

Masayuki Nagasawa,Tomohiro Udagawa,Tomoyuki Kato,Ippei Tanaka,Ren Yamamoto,Hayato Sakaguchi,Yoshiyuki Sekikawa

DOI: https://doi.org/10.3390/pathogens13110983

IF: 3.7

2024-11-10

Pathogens

Abstract:The impact of common respiratory virus infections on adults and older individuals in the community is unclear, excluding seasonal influenza viruses. We examined FilmArray® tests performed on 1828 children aged 60 years with rhinovirus/enterovirus (RV/EV), respiratory syncytial virus (RSV), parainfluenza virus-3 (PIV-3), or human metapneumovirus (hMPV) infection required hospitalization, of whom seven died; 26 out of 160 patients (16.3%) aged < 60 years required hospitalization mostly because of deterioration of bronchial asthma, with no reported deaths. In older patients with RV/EV infection, three with few respiratory symptoms died due to worsened heart failure. Although the frequency of common respiratory virus infections in older adults is low, it may be overlooked because of subclinical respiratory symptoms, and its clinical significance in worsening comorbidities in older adults should not be underestimated.

microbiology
Burden of respiratory syncytial virus, human metapneumovirus and influenza virus infections in Japanese adults in the Hospitalized Acute Respiratory Tract Infection study

Masaharu Shinkai,Shinichiro Ota,Nobuhisa Ishikawa,Takuya Tanimoto,Hiroki Suzuki,Shuichi Abe,Yannick Vandendijck,Yoshikazu Nakayama,Yoko Murata

DOI: https://doi.org/10.1016/j.resinv.2024.05.015

Abstract:Background: Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and influenza virus are responsible for acute respiratory tract infections (ARTIs) in adults. We assessed the clinical burden of RSV, hMPV and influenza virus infection among Japanese adults hospitalized with ARTIs. Methods: The Hospitalized Acute Respiratory Tract Infection (HARTI) study was a multinational, prospective cohort study in adults with ARTIs across the 2017-2019 epidemic seasons. Enrolment in Japan began in Sept 2018 and ran until Oct 2019. The clinical diagnosis of ARTI and the decision to hospitalize the patient were made according to local standard of care practices. Viral testing was performed by reverse transcription polymerase chain reaction. Results: Of the 173 adults hospitalized with ARTI during this period at the Japan sites, 7 (4.0%), 9 (5.2%), and 11 (6.4%) were positive for influenza virus, RSV, and hMPV, respectively. RSV season was observed from Oct 2018 to Jan 2019, followed by influenza from Dec 2018 to Apr 2019. hMPV was detected across both the RSV and influenza seasons. Two patients with RSV and 1 patient with hMPV required ICU admission whereas none with influenza. Use of antibiotics, bronchodilators and inhaled corticosteroids was high amongst patients with RSV and hMPV at 1, 2, and 3 months' post-discharge compared with patients with influenza, with few exceptions. Conclusion: These findings highlight the need for a high degree of clinical suspicion for RSV and hMPV infection in adults hospitalized with ARTIs.
Influenza Vaccination And Hospitalization Outcomes Among Older Patients With Cardiovascular Or Respiratory Diseases

Yuanjie Pang,Qi Wang,Min Lv,Mengke Yu,Ming Lu,Jiang Wu,Zheng Xie

DOI: https://doi.org/10.1093/infdis/jiaa493

2021-01-01

Abstract:Background: Influenza vaccination has been suggested to protect against death and recurrent events among patients with cardiovascular disease or chronic obstructive respiratory disease, but there is limited evidence in older adults, who have higher risks of influenza-associated hospitalization and mortality.Methods: Patients aged >= 60 years hospitalized for cardiovascular or respiratory diseases from the Beijing Urban Employee Basic Medical Insurance database during 3 influenza seasons (2013-2014 through 2015-2016) were pooled to estimate the effects of influenza vaccination on hospitalization outcomes. Vaccination status was ascertained through cross-referencing the Beijing Elderly Influenza Vaccination database. The summer months (June-August) were used as a reference period to adjust for unmeasured confounders during influenza seasons.Results: After adjustment for both measured and unmeasured confounders, influenza vaccination was associated with lower risks of in-hospital deaths among patients hospitalized for cardiovascular (odds ratio [95% confidence interval], 0.85 [.68-1.06]) or respiratory diseases (0.66 [.54-.82]). Influenza vaccination was associated with a lower risk of readmission among patients with cardiovascular (odds ratio [95% confidence interval], 0.81 [.69-.95]) but not respiratory diseases (1.12 [.92-1.35]). Influenza vaccination was also associated with lower direct medical costs, but not with length of stay.Conclusions: Influenza vaccination protected against hospitalization outcomes among older adults with cardiovascular or respiratory diseases.
Severe Acute Respiratory Infection (SARI) due to Influenza in Post‐COVID Resurgence: Disproportionate Impact on Older Māori and Pacific Peoples

Isabella M. Y. Cheung,Janine Paynter,David Broderick,Adrian Trenholme,Cass A. Byrnes,Cameron C. Grant,S. Qiu Huang,Nikki Turner,Peter McIntyre

DOI: https://doi.org/10.1111/irv.70029

2024-10-31

Influenza and Other Respiratory Viruses

Abstract:Influenza and Other Respiratory Viruses, Volume 18, Issue 11, November 2024.

infectious diseases,virology
Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan

Kosuke Tamura,Reiko Shimbashi,Ayu Kasamatsu,Bin Chang,Kenji Gotoh,Yoshinari Tanabe,Koji Kuronuma,Kengo Oshima,Takaya Maruyama,Masashi Nakamatsu,Shuichi Abe,Kei Kasahara,Junichiro Nishi,Yu Arakawa,Yuki Kinjo,Motoi Suzuki,Yukihiro Akeda,Kazunori Oishi,Adult Ipd Study Group,Adult IPD Study Group

DOI: https://doi.org/10.1016/j.ijid.2024.107024

IF: 12.073

2024-04-07

International Journal of Infectious Diseases

Abstract:Objective : We aimed to investigate the impact of preceding seasonal influenza on the clinical characteristics of adult patients with invasive pneumococcal disease (IPD) in Japan. Methods : Data for 1,722 adult patients with IPD were analyzed before (2017–2019) and during the COVID-19 pandemic (2020–2022). Results : Seasonal influenza epidemic disappeared soon after the emergence of the pandemic. Compared with that before the pandemic (66.7%), we observed a lower bacteremic pneumonia proportion in patients with IPD during the pandemic (55.6%). The clinical presentations of IPD cases significantly differed between those with and without preceding influenza. The proportion of bacteremic pneumonia was higher in IPD patients with preceding influenza than in those without in both younger (44.9% vs. 84.2%) and older adults (65.5% vs. 87.0%) before the pandemic. The case fatality rate was significantly higher in IPD patients with preceding influenza (28.3%) than in those without (15.3%) in older adults before the pandemic (P = 0.020). Male and aging are high risk factors for death in older patients with IPD who had preceding influenza. Conclusion : Our study reveals that preceding seasonal influenza plays a role in the development of bacteremic pneumococcal pneumonia, increasing the risk of death in older adults.

infectious diseases
Characterizing the seasonal influenza disease burden attributable to climate variability: A nationwide time-series modelling study in Japan, 2000-2019

Keita Wagatsuma,Lina Madaniyazi,Chris Fook Sheng Ng,Reiko Saito,Masahiro Hashizume

DOI: https://doi.org/10.1016/j.envres.2024.120065

2024-09-26

Abstract:Background: Ambient temperature and humidity are established environmental stressors with regard to influenza infections; however, mapping disease burden is difficult owing to the complexities of the underlying associations and differences in vulnerable population distributions. In this study, we aimed to quantify the burden of influenza attributable to non-optimal ambient temperature and absolute humidity in Japan considering geographical differences in vulnerability. Methods: The exposure-lag-response relationships between influenza incidence, ambient temperature, and absolute humidity in all 47 Japanese prefectures for 2000-2019 were quantified using a distributed lag non-linear model for each prefecture; the estimates from all the prefectures were then pooled using a multivariate mixed-effects meta-regression model to derive nationwide average associations. Association between prefecture-specific indicators and the risk were also examined. Attributable risks were estimated for non-optimal ambient temperature and absolute humidity according to the exposure-lag-response relationships obtained before. Results: A total of 25,596,525 influenza cases were reported during the study period. Cold and dry conditions significantly increased influenza incidence risk. Compared with the minimum incidence weekly mean ambient temperature (29.8 °C) and the minimum incidence weekly mean absolute humidity (20.2 g/m3), the cumulative relative risks (RRs) of influenza in cold (2.5 °C) and dry (3.6 g/m3) conditions were 2.79 (95% confidence interval [CI]: 1.78-4.37) and 3.20 (95% CI: 2.37-4.31), respectively. The higher RRs for cold and dry conditions were associated with geographical and climatic indicators corresponding to the central and northern prefectures; demographic, socioeconomic, and health resources indicators showed no clear trends. Finally, 27.25% (95% empirical CI [eCI]: 5.54-36.35) and 32.35% (95% eCI: 22.39-37.87) of all cases were attributable to non-optimal ambient temperature and absolute humidity (6,976,300 [95% eCI: 1,420,068-9,306,128] and 8,280,981 [95% eCI: 8,280,981-9,693,532] cases), respectively. Conclusions: These findings could help identify the most vulnerable populations in Japan and design adaptation policies to reduce the attributable burden of influenza due to climate variability.
The Clinical Effect of Seasonal Flu Vaccination on Health-Related Quality of Life

Yusuke Yoshino,Yoshitaka Wakabayashi,Takatoshi Kitazawa

DOI: https://doi.org/10.2147/IJGM.S309920

IF: 2.145

2021-05-27

International Journal of General Medicine

Abstract:Yusuke Yoshino, 1, 2 Yoshitaka Wakabayashi, 1 Takatoshi Kitazawa 1 1 Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan; 2 Department of Microbiology, Teikyo University School of Medicine, Tokyo, Japan Correspondence: Yusuke Yoshino Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan Tel +81-3-3964-1211 Email Purpose: This study aimed to determine the clinical effect of seasonal flu vaccination in adult outpatients based on the effect on health-related quality of life (HRQOL). Patients and Methods: We reviewed the clinical data of adult flu outpatients with mild symptoms who presented to the outpatient clinic of Teikyo University Hospital, Tokyo, Japan, from 2018 to 2020 winter season and were enrolled in the prospective observational study of the clinical efficacy of anti-flu agents (UMIN000034896). We evaluated influenza vaccination status, clinical symptoms, and the status of HRQOL as measured by Short Form-8 ® (SF-8 ® ) at first visit. The SF-8 ® survey generated two-component summaries; a physical component summary and a mental component summary. Results: The data of 79 patients were evaluated in this study. Of the 79 patients, 37 were vaccinated for influenza at least three weeks before contracting seasonal influenza. Not every patient needed to be hospitalized for treatment. There were no significant differences in clinical backgrounds between vaccinated patients and non-vaccinated patients. Univariate analysis showed influenza vaccination was significantly associated with higher scores on the physical component summary of HRQOL (p=0.0011). Conclusion: Influenza vaccinations would be clinically valuable for adult outpatients with seasonal flu and mild symptoms, because they can significantly inhibit the decrease of HRQOL due to influenza infection. Keywords: influenza vaccination, health-related quality of life, 8-Item Short Form Health Survey, SF-8, patient-reported outcome Influenza patients exhibit upper and/or lower respiratory tract signs and symptoms, often accompanied by systemic illness symptoms, such as fever, headache, myalgia, and weakness. Despite being a self-limiting disease, influenza can also occur in the pandemic form. Influenza pandemics often lead to serious health complications, deaths, as well as social and economic disruption. Due to health concerns for individuals and the potential for pandemics, influenza prevention, and control strategies, including vaccination, is available worldwide. Indeed, the United States Advisory Committee on Immunization Practices recommends annual influenza vaccination for all individuals six months of age and older. 1 Inactivated influenza vaccines and a live attenuated vaccine are available in the US. Only the inactivated influenza vaccine is available in Japan. The available standard-dose inactivated influenza vaccine in Japan is a quadrivalent preparation of split virions that have been inactivated. This type of vaccine is one of the major vaccines globally, approved due to its safety and clinical effectiveness. A population-based study in the United States assessed the effect of influenza vaccination on disease severity among hospitalized patients during the 2013 to 2014 influenza season. In a season in which vaccine viruses were antigenically similar to circulating viruses, influenza vaccination was associated with a reduced odds of in-hospital death among patients aged 18 to 64 years of age. 2 However, almost all seasonal flu patients are outpatients with mild symptoms such as fever or feeling feverish/chills, cough, sore throat, runny or stuffy nose, muscle aches, joint aches, headaches, fatigue, vomiting, and diarrhea. Furthermore, there are few clinical reports on the clinical benefits of flu vaccination in outpatients with mild symptoms. 3 , 4 In addition, there have been no reports on the benefit of flu vaccination evaluated by patient-reported outcomes for outpatients with mild symptoms. The aim of this research study was to determine the clinical effect of seasonal flu vaccination in adult outpatients based on the effect on Health-Related Quality of Life (HRQOL), as reported by patients. This study is a sub-analysis of the prospective observational study, approved by the ethics committee of Teikyo University (No. TUIC-COI 18–0760), which examined the therapeutic effect of anti-flu agents for seasonal flu. This trial enrolled all influenza patients visiting the outpatient clinic of the department of internal medicine of Teikyo University Ho -Abstract Truncated-

medicine, general & internal
Incidence of Influenza-Related Medical Encounters and the Associated Healthcare Resource Use and Complications Across Adult Age Groups in The United States During the 2015-2020 Influenza Seasons

Ian McGovern,Katherine Cappell,Alina N Bogdanov,Mendel D M Haag

DOI: https://doi.org/10.1093/cid/ciae180

IF: 20.999

2024-04-04

Clinical Infectious Diseases

Abstract:Background Research on influenza burden in adults has focused on crude subgroups with cut-points at 65-years, limiting insight into how burden varies with increasing age. This study describes the incidence of influenza-related outpatient visits, emergency room (ER) visits, and hospitalizations, along with healthcare resource use and complications in the aging adult population. Methods Individuals ≥18 years of age in the United States were evaluated retrospectively in five seasonal cohorts (2015–2020 seasons) in strata of age with 5-year increments. Person-level electronic medical records linked to pharmacy and medical claims were used to ascertain patient characteristics and outcomes. Influenza-related medical encounters were identified based on diagnostic codes (ICD-10 codes J09*–J11*). Results Incidence of influenza-related outpatient visits was highest among people aged 18–34 years and declined with increasing age. For ER visits, incidence tended to be elevated for people aged 18–34 years, relatively stable from 35 through 60, and increased rapidly after 60. Hospitalization incidence remained relatively stable until about 50 years of age and then increased with age. One in three patients was diagnosed with pneumonia after hospitalization, regardless of age. Across seasons, age groups, and clinical settings, on average, 40.8% of individuals were prescribed antivirals and 17.2% antibiotics. Conclusions Incidence of influenza-related hospitalizations begins to increase around age 50 rather than the more common cut-point of 65, whereas incidence of outpatient visits was highest among younger adults. Influenza infections frequently led to antiviral and antibiotic prescriptions, underscoring the role influenza vaccination can play in combating antimicrobial resistance.

immunology,infectious diseases,microbiology
Surveillance of seasonal influenza viruses during the COVID‐19 pandemic in Tokyo, Japan, 2018–2023, a single‐center study

Hidenori Takahashi,Hiroki Nagamatsu,Yuka Yamada,Naoya Toba,Mio Toyama‐Kousaka,Shinichiro Ota,Miwa Morikawa,Masahiro Shinoda,Syunsuke Takano,Suzuko Fukasawa,Kaeyoung Park,Takahiko Yano,Masamichi Mineshita,Masaharu Shinkai

DOI: https://doi.org/10.1111/irv.13248

2024-01-06

Influenza and Other Respiratory Viruses

Abstract:Introduction COVID‐19 pandemic led to significant reductions in influenza detection worldwide, fueling debates on whether influenza truly ceased circulating in communities. The number of influenza cases decreased significantly in Japan, raising concerns about the potential risk of decreased immunity to influenza in the population. Our single‐center study aimed to investigate influenza trends before and during the COVID‐19 pandemic in Tokyo, Japan. Materials and Methods This cross‐sectional study included patients of all ages who visited Tokyo Shinagawa Hospital between April 1, 2018, and March 31, 2023. Influenza and COVID‐19 tests were conducted using Quick Navi‐Flu2 and polymerase chain reaction (PCR). We analyzed data from before and during the COVID‐19 epidemic, based on patient background, hospitalization, and deaths, collected from medical records. Results A total of 12 577 influenza tests were conducted, with approximately 100 tests consistently performed each month even in the influenza off‐season. Throughout the observation period, 962 positive cases were identified. However, no cases were observed for 27 months between March 2020 and November 2022. Influenza A cases were reobserved in December 2022, followed by influenza B cases in March 2023, similar to the influenza incidence reports from Tokyo. The positivity rate during the 2022–2023 winter season was lower than before the COVID‐19 epidemic and decreased in elderly patients, with no hospitalizations or deaths observed. Conclusion This single‐center study provided actual trend data for influenza patients before and during COVID‐19 outbreaks in Tokyo, which could offer insights into the potential impact and likelihood of influenza virus infection in Japan.

infectious diseases,virology
Global burden of influenza lower respiratory tract infections in older people from 1990 to 2019

Jing-Nan Feng,Hou-Yu Zhao,Si-Yan Zhan

DOI: https://doi.org/10.1007/s40520-023-02553-1

2023-01-01

Aging Clinical and Experimental Research

Abstract:Background Infections with influenza viruses cause severe illness, substantial number of hospitalization and death, especially in older adults. However, few studies have focused on the burden of influenza lower respiratory tract infections (LRTIs) solely in older adults, particularly in low-resource settings. Aims We aimed to estimate the mortality and DALYs of influenza LRTIs for people aged 55 years and older in 204 countries and territories from 1990 to 2019. Methods The Global Burden of Disease (GBD) 2019 study was used to obtain data on mortality and DALYs of influenza LRTIs at the global, regional, and country levels. Results In 2019, the global rates for mortality and DALYs of influenza LRTIs were 6.46 per 100,000 [95% uncertainty interval (UI): 2.37–12.62] and 97.39 per 100,000 (95% UI: 34.70–187.03). Although the rates for mortality and DALYs in people aged 55 years and older decreased from 1990 to 2019, the absolute numbers for both increased by 85.84% and 66.56%, respectively. Both the absolute numbers and rates of deaths and DALYs of influenza LRTIs were higher in male than in female in all age groups. Although low-socio-demographic index (SDI) regions experienced the largest declines for the rates of mortality and DALYs of influenza LRTIs over the past three decades, they still had the highest rates for mortality and DALYs in all age groups. Moreover, the absolute numbers and rates of deaths and DALYs of influenza LRTIs showed an increasing trend with age, reaching the peak in the people over 85 years old. Discussion Burden of influenza LRTIs in older adults is still high and could continue to grow along with global aging. Conclusion Efforts to improve vaccination for influenza are needed for preparedness of another influenza pandemic, especially in low-SDI regions.
Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies

Jinxin Guo,Xin Chen,Yu Guo,Mengze Liu,Pei Li,Yiming Tao,Zhike Liu,Zhirong Yang,Siyan Zhan,Feng Sun

DOI: https://doi.org/10.1016/j.vaccine.2024.02.059

IF: 4.169

2024-02-01

Vaccine

Abstract:BACKGROUND: Under the global risk of epidemic rebound of influenza after COVID-19 outbreak, the study aimed to provide a comprehensive evaluation of the seasonal influenza vaccine effectiveness (IVE) and to explore the potential effect modifiers.METHODS: We searched for test-negative design studies with IVE estimates published between January 1, 2017 and December 31, 2022. We estimated pooled IVE using random-effects meta-analysis, and conducted meta-regression with study site, age, sex and comorbidity as explanatory variables.RESULTS: We identified 2429 publications and included 191 in the meta-analysis. The pooled IVE was 41.4 % (95 % CI: 39.2-43.5 %) against any influenza. For specific strains, the IVE was 55.4 % (95 % CI: 52.7-58.1 %) against A/H1N1, 26.8 % (95 % CI: 23.5-29.9 %) against A/H3N2, 47.2 % (95 % CI: 38.1-54.9 %) against B/Yamagata, and 40.6 % (95 % CI: 23.7-53.7 %) against B/Victoria, and the effectiveness against A/H3N2 was significantly lower than A/H1N1 (p < 0.0001) and B/Yamagata (p < 0.0001). The pooled IVE was 39.2 % (95 % CI: 36.5-41.9 %) in preventing influenza-associated outpatient visit and 43.7 % (95 % CI: 39.7-47.4 %) in preventing influenza-related hospitalization. The IVE against any influenza was 48.6 % (95 % CI: 44.7-52.2 %) for children aged < 18 years, 36.7 % (95 % CI: 31.9-41.1 %) for adults aged 18-64 years, and 30.6 % (95 % CI: 26.2-34.8 %) for elderly aged ≥65 years. Meta-regression revealed that the IVE was associated with the average age of study participants, in which both young adults [relative odds ratio (ROR) = 1.225, 95 % confidence interval (CI): 1.099-1.365, p = 0.0002] and elderly (ROR = 1.245, 95 % CI: 1.083-1.431, p = 0.002) manifested a significantly decreased effectiveness compared with children.CONCLUSIONS: Influenza vaccines provided moderate protection against laboratory-confirmed influenza and related outpatient visit and hospitalization. However, the effectiveness may vary substantially by virus type and age group, suggesting the necessity to tailor vaccination strategies especially for older individuals and against the A/H3N2 strain, and to promote annual immunization and annual analysis of vaccine effectiveness.

immunology,medicine, research & experimental

The Burden of Seasonal Influenza and Its Potential Complications Among Older Japanese Adults: A Real‐World Database Study

Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta‐analysis

Burden of influenza hospitalization among high-risk groups in the United States

The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults

Burden of respiratory syncytial virus infections in older adults with acute respiratory infection in Japan: An epidemiological study among outpatients

Impact of Age and Comorbid Conditions on Incidence Rates of COVID‐19‐Associated Hospitalizations, 2020–2021

The burden of disease and vaccine prevention of influenza in the elderly, patients with chronic diseases and health personnel

Factors associated with the development of bacterial pneumonia related to seasonal influenza virus infection: a study using a large-scale health insurance claim database

Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data

Incidence of hospitalisation for severe complications of influenza virus infection in Japanese patients between 2012 and 2016: a cross-sectional study using routinely collected administrative data

Observational Study on the Clinical Reality of Community-Acquired Respiratory Virus Infections in Adults and Older Individuals

Burden of respiratory syncytial virus, human metapneumovirus and influenza virus infections in Japanese adults in the Hospitalized Acute Respiratory Tract Infection study

Influenza Vaccination And Hospitalization Outcomes Among Older Patients With Cardiovascular Or Respiratory Diseases

Severe Acute Respiratory Infection (SARI) due to Influenza in Post‐COVID Resurgence: Disproportionate Impact on Older Māori and Pacific Peoples

Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan

Characterizing the seasonal influenza disease burden attributable to climate variability: A nationwide time-series modelling study in Japan, 2000-2019

The Clinical Effect of Seasonal Flu Vaccination on Health-Related Quality of Life

Incidence of Influenza-Related Medical Encounters and the Associated Healthcare Resource Use and Complications Across Adult Age Groups in The United States During the 2015-2020 Influenza Seasons

Surveillance of seasonal influenza viruses during the COVID‐19 pandemic in Tokyo, Japan, 2018–2023, a single‐center study

Global burden of influenza lower respiratory tract infections in older people from 1990 to 2019

Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies